Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06182527
Other study ID # 147/2023
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 27, 2023
Est. completion date December 2024

Study information

Verified date January 2024
Source University of Ulm
Contact Julia Hummel, PhD
Phone +4973150044744
Email julia.hummel@uniklinik-ulm.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research project aims to investigate the everyday relevance of reactive hypoglycemia (hypoglycemia after a glucose load) in the oral glucose tolerance test (OGTT). Therefore, blood glucose profiles in everyday life will be examined using continuous glucose measurement (Free Style Libre PRO IQ system) over a period of 14 days in affected persons.


Description:

The aim of this analysis is to examine people who underwent an OGTT due to various endocrinological and metabolic issues and developed reactive hypoglycemia, defined as a drop in blood glucose <70mg/dl during the course of the test. During OGTT routine laboratory testing will be performed as part of routine clinical practice. In order to investigate the occurrence and perception of hypoglycaemia in the everyday lives of those affected, their blood glucose profiles will be recorded and evaluated over a period of 14 days. In addition, the perception of (suspected) hypoglycemia and counteraction will be documented. Anthropometric data will be recorded and a bioelectrical impedance analysis performed to check a correlation with the body composition. Subjects will be recruited via the endocrinology outpatient clinic as part of medical care. To date, very little CGM data are available on the frequency and extent of reactive hypoglycemia in the everyday lives of people without diabetes mellitus. Therefore, 20 subjects with hypoglycemia in the OGTT will be included in this exploratory pilot study for hypothesis generation in order to investigate the occurrence and perception of hypoglycemia in everyday life.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date December 2024
Est. primary completion date October 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - hypoglycemia during a 75 g oral glucose tolerance test defined as glucose level below 70 mg/dl at timepoint 180 min. - written consent Exclusion Criteria: - diabetes mellitus - use of medication interfering with glucose metabolism (steroid, antidiabetic medications) - surgery of upper GI-tract - known plaster allergies - any other clinical condition that would endanger participants safety or question scientific success according to the physicians opinion

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Free Style Libre Pro IQ
Every participant receives a Free Style Libre Pro IQ sensor for 14 days. Glucose levels will be recorded.

Locations

Country Name City State
Germany Universityhospital Ulm Ulm

Sponsors (1)

Lead Sponsor Collaborator
University of Ulm

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of hypoglycemia Occurrence of glucose levels below 70 mg/dl assessed by CGM. 14 days
Primary Frequency of hypoglycemia Number of glucose levels below 70 mg/dl assessed by CGM. 14 days
Primary Severity of hypoglycemia Non-severe hypoglycemia defined as glucose levels < 70 mg/dl but >= 54mg/dl; severe hypoglycemia defined as glucose levels < 54mg/dl assessed by CGM. 14 days
Secondary Time of occurence of hypoglycemia Occurence of hypoglycemia during day or night time and correspondence to food intake assessed by CGM. 14 days
Secondary Perception of hypoglycemia Incidence of typical symptoms of hypoglycemia perceived by the participant, documented in a protocol with free-text fields handed out to the participant during 1st study visit. 14 days
Secondary Time in predefined glucose ranges Time spent in the following glucose ranges: time above range: >140mg/dl; time in range: 71-140mg/dl; time below range: <70mg/dl; time with severe hypoglycemia: <54mg/dl assessed by CGM. 14 days
Secondary Mean glucose levels Mean glucose levels during monitoring period assessed by CGM. 14 days
Secondary Glucose variability Glucose variability during monitoring period assessed by CGM. 14 days
Secondary Correlation between severity of hypoglycemia during ogtt and hypoglycemia in everyday life Correlation between severity of hypoglycemia during OGTT and incidence and severity of hypoglycemia in everyday life assessed by CGM. Varying time point between oGTT and 14 days of glucose assessment using CGM
Secondary Correlation between body composition and hypoglycemia in everyday life Correlation between body composition (assessed by bioelectrical impedance analysis and anthropometric measurements) and incidence as well as severity of hypoglycemia in everyday life assessed by CGM. 14 days
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03514576 - Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery Phase 4
Completed NCT03353415 - Continuous Glucose Monitoring to Reduce Hypoglycemia and Improve Safety After Gastric Surgery N/A
Completed NCT05057819 - Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass Phase 4
Terminated NCT04452396 - CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia N/A